

**Substitute for Form 1449A/PTO SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number 21007YP

**Examiner
Signature**

/Yong Chu/

Date Considered

06/09/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION ENCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				COMPLETE IF KNOWN		
<p>Sheet</p>		1	of	2	Attorney Docket Number	
						100086
						February 3, 2005
						Jeffrey M. Bergman
						To Be Assigned
				Examiner Name	To Be Assigned	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
YC	1	Arteaga, C. L. et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice", J. Clin. Invest., Vol. 84, pp. 1418-1423 (1989)
	2	Baserga, R., "Controlling IGF-receptor function: a possible strategy for tumor therapy", Trends in Biotechnology (TIBTECH), Vol. 14, pp. 150-152 (1996)
	3	Baserga, R., "Oncogenes and the Strategy of Growth Factors", Cell, Vol. 79, pp. 927-930 (1994)
	4	Baserga, R., "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?", Cancer Research, Vol. 55, pp. 249-252 (1995)
	5	Bolen J. B. et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction", The FASEB Journal, Vol. 6, pp. 3403-3409 (1992)
	6	Cance W. G., et al., "NOVEL PROTEIN KINASES EXPRESSED IN HUMAN BREAST CANCER", Int. J. Cancer, Vol. 54, pp. 571-577 (1993)
	7	Coppola, D., et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor", MOLECULAR AND CELLULAR BIOLOGY, Vol. 14, pp. 4588-4595 (1994)
	8	Goldring, M. B., et al., "Cytokines and Cell Growth Control", Eukaryotic Gene Expression, Vol. 1, pp. 301-326 (1991)
	9	Kenyon, C., et al., "A Conserved Regulatory System for Aging", Cell, Vol. 105, pp. 165-168 (2001)
	10	Khandwala, H. M., et al., "The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth", Endocrine Reviews, Vol. 21, pp. 215-244 (2000)
	11	Kimura, K. D., et al., "daf-2, an Insulin Receptor-Like Gene That Regulates Longevity and Diapause in Caenorhabditis elegans", SCIENCE, Vol. 277, pp. 942-946 (1997)
	12	Macaulay, V. M., et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells", Cancer Research, Vol. 50, pp. 2511-2517 (1990)
	13	Minet et al., "Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (Review)", International Journal of Molecular Medicine, Vol. 5, pp. 253-259 (2000)
↓	14	Plowman, G. E., et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention", DN&P, Vol. 7, pp. 334-339 (1994)
YC	15	Sandberg-Nordqvist, A. C., et al., "Characterization of Insulin-like Growth Factor 1 in Human Primary Brain Tumors", Cancer Research, Vol. 53, pp. 2475-2478 (1993)

Examiner Signature	/Yong Chu/	Date Considered	06/09/2006
--------------------	------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEI 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005

Substitute for form 1449B/PTO		COMPLETE IF KNOWN			
INFORMATION Disclosure STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10-1186		
		Filing Date	February 3, 2005		
		First Named Inventor	Jeffrey M. Bergman Christopher		
		Group Art Unit	To Be Assigned		
		Examiner Name	To Be Assigned		
Sheet	2	of	2	Attorney Docket Number	21007YP

NON PATENT LITERATURE DOCUMENTS

**Examiner
Signature**

Tony Cl

Date Considered

6-9-2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005